Arseus H1 profit beats expectations led by drug ingredients
BRUSSELS Aug 2 (Reuters) - Belgian medical equipment maker Arseus posted better-than-expected core profit in the first half of 2013, led by a surge in profitability at its Fagron unit which sells medical ingredients to pharmacies.
Recurring core profit (REBITDA) rose 29.9 percent in the first-half of 2013 to 50.4 million euros ($66.70 million), it said on Friday. That was better than the 45 million euros expected in a Reuters consensus.
It said that for 2013 it expected healthy organic growth with profitability growing faster than turnover. ($1 = 0.7557 euros) (Reporting by Robert-Jan Bartunek)
- Female Yahoo executive sued for sexual harassment
- Gaza toll passes 100; Israel to counter rockets 'with all power' |
- Ukraine says rebels will pay as missiles kill 23 soldiers |
- Ebola deaths surge in Sierra Leone and Liberia: WHO
- German suspect was in contact with State Dept not U.S. spies: officials